Methods of treatment using novel LHRH antagonists having...

Details Methods of treatment using novel LHRH antagonists having... Methods of treatment using novel LHRH antagonists having...

2006-07-24

2010-06-08

Gupta, Anish (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S328000

Reexamination Certificate

active

07732412

ABSTRACT:
The invention relates to peptides which contain N-methylated amino acid units and have improved water solubility. The invention also relates methods for treating a hormone-dependent tumor or a non-malignant indication that is treatable by LH-RH suppression, the method comprising administering to a patient in need of the treatment a therapeutically effective amount of a compound of the invention. Hormone-dependent cancers that can be treated with the methods of the invention include prostate cancer, breast cancer, ovarian cancer, endometrial cancer, and pancreatic cancer. Non-malignant indications which can be treated by the methods of the invention include benign prostate hyperplasia (BPH), endometriosis, acne, polycystic ovarian disease, dysmenorrhea, precocious puberty, and uterine fibroids and other leiomyomas.

REFERENCES:
patent: 4581169 (1986-04-01), Nestor et al.
patent: 4628044 (1986-12-01), Loozen
patent: 5198533 (1993-03-01), Schally et al.
patent: 5300492 (1994-04-01), Haviv et al.
patent: 5527777 (1996-06-01), Thamm et al.
patent: 5942493 (1999-08-01), Kutscher et al.
patent: 6054432 (2000-04-01), Engel et al.
patent: 6586403 (2003-07-01), Mathison et al.
patent: 2004/0259801 (2004-12-01), Damm et al.
patent: 195 44 212 (1997-06-01), None
patent: 0 328 090 (1989-08-01), None
patent: 0 413 209 (1991-02-01), None
patent: 0417454 (1991-03-01), None
patent: WO 97/19953 (1997-06-01), None
patent: WO 98/25642 (1998-06-01), None
patent: WO 00/55190 (2000-09-01), None
Engel JB et al., New peptidic GnRH antagonists offer a broad range of therapeutic applications, 2005, Letters in Drug Design and Discovery, 2:533-536.
Registry information for Ozarelix, 1 page.
Haviv et al., “The Effect of NmeTyr5Substitution in Luteinizing Hormone-Releasing Hormone Antagonists”,J. Med. Chem., 1993, vol. 36, No. 7, pp. 928-933.
Dermer, Another Anniversary for the War on Cancer,Bio/Technology, 1994, vol. 12, p. 320.
Palatsi et al., “Pituitary function and DHEA-S in male acne and DHEA-S, prolactin and cortisol before and after oral contraceptive treatment in female acne,” Acta. Derma. Venerol., 66:225-30 (1986) (abstract only).

Affiliated with

Also associated with

Rating

Methods of treatment using novel LHRH antagonists having... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treatment using novel LHRH antagonists having..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment using novel LHRH antagonists having... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4245976